CRL Charles River Laboratories International, Inc. Common Stock
$288,77
Preço · Ago 18, 2026
Fundamentais a partir de Ago 5, 2026
Intervalo 52 Semanas
$144–$289
100% of range
Classificação do Analista
BUY
22 analysts
Preço-Alvo
$281
P/E (TTM)
-99.2
ROE
-4.4%
Margem de Lucro Líquido
-3.6%
Sobre Charles River Laboratories International, Inc. Common Stock Visão geral da empresa da Wikipedia
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Ler mais
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M USD.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
CRL Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$288.77
Capitalização de Mercado
$14.21B
P/E (TTM)
-99.2
EPS (TTM)
$-2.91
Receita (TTM)
$4.02B
Rendimento div.
—
ROE
-4.4%
Dívida/Capital
0.0
Intervalo 52 Semanas
$144 – $289
CRL Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$4.02B
2016-12-31
→
2025-12-27
EPS
$-2.91
2016-12-31
→
2025-12-27
Fluxo de caixa livre
$518M
2016-12-31
→
2025-12-27
Margens
-3.6%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
CRL
Mediana de Pares
P/E (TTM)
-99.2
39.9
P/S (TTM)
3.5
5.6
P/B
4.5
4.1
EV / EBITDA
32.7
—
Price / FCF (Preço / FCF)
27.4
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
CRL
Mediana de Pares
Operating Margin (Margem Operacional)
0.63%
—
Net Profit Margin (Margem de Lucro Líquido)
-3.6%
11.7%
ROA
-2.0%
4.7%
ROE
-4.4%
8.5%
ROIC
1.1%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
CRL
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
0.0
15.3
Current Ratio (Índice de liquidez corrente)
1.3
1.7
Quick Ratio (Índice de Liquidez Seca)
0.8
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
CRL
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
-0.85%
—
Revenue CAGR 3Y (CAGR Receita 3A)
0.33%
—
Revenue CAGR 5Y (CAGR Receita 5A)
6.6%
—
EPS YoY
-97.8%
—
Net Income YoY (Lucro Líquido Ano a Ano)
-95.3%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
CRL
Mediana de Pares
CRL Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
22 analistas
- Compra forte 5 22,7%
- Compra 10 45,5%
- Manter 7 31,8%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
14 analistas · 2026-08-14
Mediana
$300.00
Média
$281.00
Agora
$288.77
Mín
$145.00
Máx
$318.00
Alvo mediano
$300.00
+3,9%
Alvo médio
$281.00
-2,7%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.21%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $3.02 | $2.76 | 0.26% |
| 31 de Março de 2026 | $2.06 | $1.96 | 0.10% |
| 31 de Dezembro de 2025 | $2.39 | $2.37 | 0.02% |
| 30 de Setembro de 2025 | $2.43 | $2.36 | 0.07% |
| 30 de Junho de 2025 | $3.12 | $2.52 | 0.60% |
| 31 de Março de 2025 | $2.34 | $2.10 | 0.24% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | — |
| TECH | $7.97B | 111.8 | 5.2% | 6.0% | 3.7% | 64.8% |
| BIO | — | — | — | — | — | — |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 15
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Balanço Patrimonial 30
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Fluxo de Caixa 18
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Taxas de Crescimento 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Demonstração de Resultados 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | -99,475,000 | 49,213,000 | 49,149,000 | 50,677,000 | -103,002,000 | 51,394,000 | 51,551,000 | 51,437,000 | 28,000 | 51,283,000 | 51,097,000 | -101,521,000 | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | -100,031,000 | 49,426,000 | 49,316,000 | 50,853,000 | -103,643,000 | 51,583,000 | 51,846,000 | 51,842,000 | -42,000 | 51,607,000 | 51,428,000 | -102,590,000 | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Balanço Patrimonial 28
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Fluxo de Caixa 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Lucratividade 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Liquidez e Solvência 4
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Avaliação (TTM) 13
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.04B | $4.02B | · | $4.03B | $4.05B | $4.03B | · | $4.07B | $4.12B | $4.13B | · | $4.11B | $3.91B | · | $3.77B | |
| Net Income TTM | $90M | $117M | · | $202M | $242M | $262M | · | $324M | $351M | $360M | · | $384M | $402M | · | $402M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | 117.9 | 67.4 | · | 37.2 | 32.4 | 31.9 | · | 32.7 | 31.2 | 39.3 | · | 26.2 | 25.8 | · | 23.9 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | · | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| P / FCF | · | -516.9 | · | · | · | 68.0 | · | · | · | 275.0 | · | · | · | · | · | |
| EV / EBITDA | 54.0 | 40.0 | · | 32.4 | 32.8 | 38.0 | · | 48.3 | 44.1 | 64.5 | · | 43.0 | · | · | 41.4 | |
| EV / FCF | · | -504.4 | · | · | · | 65.9 | · | · | · | 268.6 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.5 | 3.3 | · | 2.4 | · | · | 2.5 | |
| Earnings Yield | 0.85% | 1.5% | · | 2.7% | 3.1% | 3.1% | · | 3.1% | 3.2% | 2.5% | · | 3.8% | 3.9% | · | 4.2% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Receita | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Margem Operacional % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Lucro líquido | $-144M | $22M | $475M | $486M | $391M |
| EPS Diluído | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
Balanço Patrimonial
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Índice de liquidez corrente | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Índice de Liquidez Seca | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
Fluxo de Caixa
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $518M | $502M | $365M | $295M | $532M |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 616 declarantes · $7.8B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 82 (-1 vs trimestre anterior) | 59 (-23 vs trimestre anterior) | 180 (-11 vs trimestre anterior) | 201 (+15 vs trimestre anterior) | +5.0M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| FMR LLC | $737.350.307 | 3.251.247 | 9,42% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $714.227.026 | 3.149.288 | 9,12% | Ações |
| HARRIS ASSOCIATES L P | $508.269.048 | 2.241.144 | 6,49% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501.427.927 | 2.210.979 | 6,40% | Ações |
| STATE STREET CORP | $422.800.968 | 1.864.284 | 5,40% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $348.883.077 | 1.538.354 | 4,46% | Ações |
| CITADEL ADVISORS LLC | $270.696.771 | 1.193.601 | 3,46% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $259.130.041 | 1.144.937 | 3,31% | Ações |
| EARNEST PARTNERS LLC | $254.007.295 | 1.120.011 | 3,24% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $223.361.616 | 984.883 | 2,85% | Ações |
| AMERIPRISE FINANCIAL INC | $192.886.814 | 850.503 | 2,46% | Ações |
| NEUBERGER BERMAN GROUP LLC | $192.182.793 | 847.488 | 2,45% | Ações |
| Clearbridge Investments, LLC | $177.185.527 | 781.276 | 2,26% | Ações |
| COOKE & BIELER LP | $171.369.328 | 755.630 | 2,19% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $150.762.735 | 664.768 | 1,93% | Ações |
| MILLENNIUM MANAGEMENT LLC | $110.324.717 | 486.462 | 1,41% | Ações |
| BANK OF AMERICA CORP /DE/ | $104.921.899 | 462.639 | 1,34% | Ações |
| Gotham Asset Management, LLC | $98.233.181 | 433.146 | 1,25% | Ações |
| Amundi | $93.528.650 | 412.402 | 1,19% | Ações |
| NORGES BANK | $83.921.372 | 370.040 | 1,07% | Ações |
| MARSHALL WACE, LLP | $76.947.125 | 339.288 | 0,98% | Ações |
| Iron Triangle Partners LP | $75.748.141 | 379.728 | 0,97% | Ações |
| ALLIANCEBERNSTEIN L.P. | $64.615.913 | 374.585 | 0,83% | Ações |
| SNYDER CAPITAL MANAGEMENT L P | $63.899.443 | 281.756 | 0,82% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63.174.169 | 278.558 | 0,81% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $63.095.473 | 278.211 | 0,81% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $61.384.115 | 270.665 | 0,78% | Ações |
| PRIMECAP MANAGEMENT CO/CA/ | $60.523.448 | 266.870 | 0,77% | Ações |
| GOLDMAN SACHS GROUP INC | $57.319.812 | 252.744 | 0,73% | Ações |
| Meridiem Capital Partners LP | $56.012.367 | 246.979 | 0,72% | Ações |
| Alyeska Investment Group, L.P. | $53.295.650 | 235.000 | 0,68% | Ações |
| Quantinno Capital Management LP | $49.020.824 | 216.150 | 0,63% | Ações |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $48.415.129 | 213.480 | 0,62% | Ações |
| Boston Trust Walden Corp | $46.506.918 | 205.066 | 0,59% | Ações |
| Burgundy Asset Management Ltd. | $45.453.909 | 278.329 | 0,58% | Ações |
| SRS Investment Management, LLC | $42.496.817 | 187.384 | 0,54% | Ações |
| LOOMIS SAYLES & CO L P | $38.517.487 | 169.838 | 0,49% | Ações |
| JONES FINANCIAL COMPANIES LLLP | $37.184.513 | 172.350 | 0,47% | Ações |
| PERCEPTIVE ADVISORS LLC | $31.750.600 | 140.000 | 0,41% | Ações |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $30.389.860 | 134.000 | 0,39% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $29.879.583 | 131.750 | 0,38% | Ações |
| BlackRock, Inc. | $29.025.945 | 127.986 | 0,37% | Ações |
| PICTON MAHONEY ASSET MANAGEMENT | $26.340.305 | 116.144 | 0,34% | Ações |
| FIL Ltd | $25.184.576 | 111.048 | 0,32% | Ações |
| Candriam S.C.A. | $23.824.478 | 105.152 | 0,30% | Ações |
| Clark Capital Management Group, Inc. | $23.010.567 | 101.462 | 0,29% | Ações |
| Vanguard Global Advisers, LLC | $22.453.344 | 99.005 | 0,29% | Ações |
| Swiss National Bank | $22.452.210 | 99.000 | 0,29% | Ações |
| CONFLUENCE INVESTMENT MANAGEMENT LLC | $20.491.384 | 90.354 | 0,26% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $20.280.546 | 89.424 | 0,26% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.730.730 | 87.000 | 0,25% | Opção de compra |
| NOMURA HOLDINGS INC | $19.672.672 | 86.744 | 0,25% | Ações |
| RHUMBLINE ADVISERS | $19.484.825 | 85.916 | 0,25% | Ações |
| Ilex Capital Partners (UK) LLP | $18.413.760 | 81.193 | 0,24% | Ações |
| Aristotle Capital Boston, LLC | $18.273.438 | 80.574 | 0,23% | Ações |
| CITADEL ADVISORS LLC | $17.485.509 | 77.100 | 0,22% | Opção de compra |
| NICHOLAS COMPANY, INC. | $16.305.067 | 71.895 | 0,21% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $15.172.024 | 66.899 | 0,19% | Ações |
| Mitsubishi UFJ Asset Management Co., Ltd. | $15.164.087 | 66.864 | 0,19% | Ações |
| Ranger Investment Management, L.P. | $15.009.416 | 66.182 | 0,19% | Ações |
| California Public Employees Retirement System | $14.670.818 | 64.689 | 0,19% | Ações |
| Assenagon Asset Management S.A. | $14.020.385 | 61.821 | 0,18% | Ações |
| ASSETMARK, INC | $13.939.194 | 61.463 | 0,18% | Ações |
| Rhenman & Partners Asset Management AB | $12.972.388 | 57.200 | 0,17% | Ações |
| RIVERBRIDGE PARTNERS LLC | $12.859.587 | 56.703 | 0,16% | Ações |
| TD Asset Management Inc | $12.854.230 | 56.679 | 0,16% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $12.836.314 | 56.600 | 0,16% | Opção de venda |
| Laurus Investment Counsel Inc. | $12.365.663 | 71.685 | 0,16% | Ações |
| KING LUTHER CAPITAL MANAGEMENT CORP | $12.204.023 | 53.812 | 0,16% | Ações |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $11.552.133 | 50.938 | 0,15% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $10.732.081 | 47.278 | 0,14% | Ações |
| RAYMOND JAMES FINANCIAL INC | $10.506.727 | 46.328 | 0,13% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $10.472.482 | 46.177 | 0,13% | Ações |
| KENNEDY CAPITAL MANAGEMENT LLC | $9.914.950 | 43.719 | 0,13% | Ações |
| BARCLAYS PLC | $9.909.816 | 43.696 | 0,13% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $9.827.670 | 56.972 | 0,13% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9.382.529 | 41.371 | 0,12% | Ações |
| Park West Asset Management LLC | $9.343.748 | 41.200 | 0,12% | Ações |
| State of Tennessee, Department of Treasury | $8.457.000 | 37.290 | 0,11% | Ações |
| J.P. Marvel Investment Advisors, LLC | $8.456.092 | 37.286 | 0,11% | Ações |
| CASTLEARK MANAGEMENT LLC | $8.174.646 | 36.045 | 0,10% | Ações |
| JANE STREET GROUP, LLC | $7.869.613 | 34.700 | 0,10% | Opção de compra |
| Pine Ridge Advisers LLC | $7.710.860 | 34.000 | 0,10% | Ações |
| PRUDENTIAL FINANCIAL INC | $7.346.635 | 32.394 | 0,09% | Ações |
| Capricorn Fund Managers Ltd | $7.092.630 | 31.274 | 0,09% | Ações |
| STATE OF WISCONSIN INVESTMENT BOARD | $7.000.554 | 30.868 | 0,09% | Ações |
| FIRST TRUST ADVISORS LP | $6.951.290 | 30.651 | 0,09% | Ações |
| Caption Management, LLC | $6.803.700 | 30.000 | 0,09% | Opção de venda |
| Engineers Gate Manager LP | $6.637.463 | 29.267 | 0,08% | Ações |
| LAWSON KROEKER INVESTMENT MANAGEMENT INC/NE | $6.351.027 | 28.004 | 0,08% | Ações |
| Midwest Trust Co | $6.091.126 | 26.858 | 0,08% | Ações |
| VAN ECK ASSOCIATES CORP | $5.942.578 | 26.203 | 0,08% | Ações |
| SEI INVESTMENTS CO | $5.929.630 | 26.150 | 0,08% | Ações |
| Sendero Wealth Management, LLC | $5.909.468 | 26.057 | 0,08% | Ações |
| 13D Management LLC | $5.851.182 | 25.800 | 0,07% | Ações |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $5.500.853 | 31.889 | 0,07% | Ações |
| D. E. Shaw & Co., Inc. | $5.462.691 | 24.087 | 0,07% | Ações |
| INVESTMENT HOUSE LLC | $5.447.042 | 24.018 | 0,07% | Ações |
| LPL Financial LLC | $5.409.169 | 23.851 | 0,07% | Ações |
| LRT Capital Management, LLC | $5.348.842 | 23.585 | 0,07% | Ações |
Executivos da empresa 57 insiders · 21 diretores · 27 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Glenn Coleman | EVP & Chief Financial Officer | 29 de Maio de 2026 A | 27.752 | 0 | 0 | $0 |
| Flavia Pease | Corporate Executive VP & CFO | 31 de Maio de 2025 F | 17.297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | 3 de Março de 2022 M | 25.819 | 0 | 0 | $0 |
| Davide Molho | President & COO | 24 de Julho de 2018 M | 17.155 | 0 | 0 | $0 |
| Mark Mintz | EVP, Chief Information Officer | 31 de Maio de 2026 F | 9.546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | 7 de Novembro de 2024 G | 23.337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | 1 de Junho de 2020 A | 3.171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | 29 de Maio de 2020 A | 224.478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | 1 de Outubro de 2016 F | 5.599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | 2 de Março de 2016 S | 11.034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | 25 de Fevereiro de 2015 M | 14.094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | 11 de Agosto de 2010 F | 74.390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | 26 de Fevereiro de 2010 A | 31.897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | 11 de Agosto de 2007 F | 37.109 | 0 | 0 | $0 |
| David J Elliott | Officer | 29 de Junho de 2007 M | 11.750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | 1 de Maio de 2007 A | 6.262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | 2 de Abril de 2007 A | 11.500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | 2 de Abril de 2007 F | 12.713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | 23 de Fevereiro de 2007 A | 12.710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | 27 de Fevereiro de 2006 S | 16.134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | 23 de Dezembro de 2004 M | 8.000 | 0 | 0 | $0 |
| Steven Barg | Conselheiro | 2 de Junho de 2026 A | 3.287 | 0 | 0 | $0 |
| Nancy C Andrews | Conselheiro | 12 de Maio de 2026 G | 3.964 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Conselheiro | 8 de Maio de 2026 A | 4.563 | 0 | 0 | $0 |
| George Llado | Conselheiro | 8 de Maio de 2026 A | 6.702 | 0 | 0 | $0 |
| Abraham Ceesay | Conselheiro | 8 de Maio de 2026 A | 2.384 | 0 | 0 | $0 |
| Mark J Enyedy | Conselheiro | 8 de Maio de 2026 A | 2.384 | 0 | 0 | $0 |
| Paul W Graves | Conselheiro | 8 de Maio de 2026 A | 2.384 | 0 | 0 | $0 |
| Craig B. Thompson | Conselheiro | 8 de Maio de 2026 A | 3.851 | 0 | 0 | $0 |
| Martin Mackay | Conselheiro | 8 de Maio de 2026 A | 17.137 | 0 | 0 | $0 |
| Virginia M Wilson | Conselheiro | 8 de Maio de 2026 A | 6.349 | 0 | 0 | $0 |
| George Massaro | Conselheiro | 15 de Maio de 2025 S | 5.575 | 0 | 0 | $0 |
| Richard F Wallman | Conselheiro | 7 de Novembro de 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Conselheiro | 13 de Maio de 2024 A | 7.894 | 0 | 0 | $0 |
| Robert J Bertolini | Conselheiro | 13 de Maio de 2024 A | 32.802 | 0 | 0 | $0 |
| Richard C Reese | Conselheiro | 15 de Maio de 2023 A | 65.541 | 0 | 0 | $0 |
| George M Milne JR | Conselheiro | 7 de Maio de 2021 A | 29.079 | 0 | 0 | $0 |
| Stephen D Chubb | Conselheiro | 23 de Fevereiro de 2021 M | 40.529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Conselheiro | 22 de Maio de 2019 A | 3.886 | 0 | 0 | $0 |
| William Waltrip | Conselheiro | 5 de Dezembro de 2012 S | 21.830 | 0 | 0 | $0 |
| Samuel O Thier MD | Conselheiro | 9 de Maio de 2012 A | 18.230 | 0 | 0 | $0 |
| Douglas E Rogers | Conselheiro | 7 de Maio de 2010 A | 12.859 | 0 | 0 | $0 |
| Nancy T Chang | Conselheiro | 7 de Maio de 2010 A | 31.010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Conselheiro | 13 de Fevereiro de 2006 A | — | 0 | 0 | $0 |
| Walter S Nimmo | Conselheiro | 25 de Fevereiro de 2005 S | 149.447 | 0 | 0 | $0 |
| John Urquhart | Conselheiro | 17 de Fevereiro de 2005 A | 11.738 | 0 | 0 | $0 |
| Louise S Mccrary | Conselheiro | 17 de Fevereiro de 2005 A | — | 0 | 0 | $0 |
| Robert Cawthorn | Conselheiro | 2 de Junho de 2004 G | 278.600 | 0 | 0 | $0 |
| Shannon M Parisotto | — | 11 de Agosto de 2026 M | 4.807 | 0 | 2 | $-2.365.755 |
| Birgit Girshick | — | 11 de Agosto de 2026 M | 36.013 | 0 | 1 | $-1.819.350 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 6 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 declarações | 4 de Agosto de 2011 | — | Declaração inicial | — | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 declarações | 9 de Fevereiro de 2011 | — | Declaração inicial | — | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 declarações | 7 de Dezembro de 2010 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 16 de Junho de 2010 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 7 de Junho de 2010 | — | Declaração inicial | Investimento passivo | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | 5 de Maio de 2010 | — | Declaração inicial | Campanha no conselho | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 135 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| RSPH · Invesco Exchange-Traded Fund Trust | 2,18% | 63.652 SH | 8 de Agosto de 2026 | Diário |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,49% | 4.749 NS | 30 de Abril de 2026 | N-PORT |
| EPSB · Harbor ETF Trust | 1,33% | 370 NS | 30 de Abril de 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 1,18% | 41.597 SH | 8 de Agosto de 2026 | Diário |
| EPMV · Harbor ETF Trust | 1,09% | 291 NS | 30 de Abril de 2026 | N-PORT |
| IBB · iShares Trust | 0,97% | 349.491 SH | 8 de Agosto de 2026 | Diário |
| EPSV · Harbor ETF Trust | 0,90% | 270 NS | 30 de Abril de 2026 | N-PORT |
| TAX · EA Series Trust | 0,80% | 1.131 NS | 29 de Maio de 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,66% | 612 NS | 30 de Abril de 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0,50% | 2.356 NS | 30 de Abril de 2026 | N-PORT |
| ISCV · iShares Trust | 0,40% | 10.497 SH | 8 de Agosto de 2026 | Diário |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,38% | 11.925 NS | 30 de Abril de 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,38% | 25.401 SH | 8 de Agosto de 2026 | Diário |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | 0,36% | 1.145.000 PA | 8 de Agosto de 2026 | Diário |
| IQSM · New York Life Investments ETF Trust | 0,33% | 6.161 NS | 30 de Abril de 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,29% | 22.440 NS | 30 de Abril de 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,27% | 996.151 SH | 8 de Agosto de 2026 | Diário |
| DFAT · Dimensional ETF Trust | 0,26% | 212.321 NS | 30 de Abril de 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,23% | 701.498 SH | 8 de Agosto de 2026 | Diário |
| ESML · iShares Trust | 0,23% | 24.979 SH | 8 de Agosto de 2026 | Diário |
| BKMC · BNY Mellon ETF Trust | 0,22% | 8.115 NS | 30 de Abril de 2026 | N-PORT |
| IYH · iShares Trust | 0,21% | 29.370 SH | 8 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | 0,20% | 2.125 SH | 8 de Agosto de 2026 | Diário |
| SMMD · iShares Trust | 0,17% | 24.455 SH | 8 de Agosto de 2026 | Diário |
| FSMD · FIDELITY COVINGTON TRUST | 0,17% | 24.528 NS | 30 de Abril de 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,17% | 133.341 NS | 31 de Maio de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,16% | 138.243 NS | 30 de Abril de 2026 | N-PORT |
| IXJ · iShares Trust | 0,16% | 25.598 SH | 8 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,16% | 148.331 SH | 8 de Agosto de 2026 | Diário |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 18.369 NS | 30 de Abril de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,15% | 6.079 NS | 31 de Maio de 2026 | N-PORT |
| WSML · iShares Trust | 0,13% | 6.018 SH | 8 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,13% | 22.674 NS | 30 de Abril de 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,13% | 59.338 NS | 30 de Abril de 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,13% | 1.102.914 SH | 8 de Agosto de 2026 | Diário |
| VGMS · VANGUARD MALVERN FUNDS | 0,13% | 315.000 PA | 8 de Agosto de 2026 | Diário |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,13% | 4.072 SH | 8 de Agosto de 2026 | Diário |
| RXL · ProShares Trust | 0,13% | 513 NS | 31 de Maio de 2026 | N-PORT |
| IWS · iShares Trust | 0,13% | 74.284 SH | 8 de Agosto de 2026 | Diário |
| REVS · Columbia ETF Trust I | 0,12% | 2.082 NS | 30 de Abril de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,12% | 982 NS | 30 de Abril de 2026 | N-PORT |
| SMLF · iShares Trust | 0,12% | 18.532 SH | 8 de Agosto de 2026 | Diário |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,11% | 3.280 NS | 30 de Abril de 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0,11% | 1.032 NS | 30 de Abril de 2026 | N-PORT |
| IWR · iShares Trust | 0,09% | 199.595 SH | 8 de Agosto de 2026 | Diário |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,09% | 1.986 NS | 31 de Maio de 2026 | N-PORT |
| IEUS · iShares Trust | 0,09% | 4.951 SH | 8 de Agosto de 2026 | Diário |
| XOEF · iShares Trust | 0,07% | 61 SH | 8 de Agosto de 2026 | Diário |
| VSDB · VANGUARD MALVERN FUNDS | 0,07% | 635.000 PA | 8 de Agosto de 2026 | Diário |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 5.261 NS | 30 de Abril de 2026 | N-PORT |